文献速递肝病

丙酮酸脱氢酶复合体和乳酸脱氢酶是急性肝衰竭治疗的靶点

Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure.
PubMed 文献 · J Hepatol · 2018-03-24

该研究在小鼠急性肝衰竭模型中观察到丙酮酸脱氢酶复合体(PDHC)和乳酸脱氢酶(LDH)转位至肝细胞核,导致核内乙酰辅酶A和乳酸浓度升高及组蛋白H3超乙酰化,进而诱导损伤反应基因表达。使用组蛋白乙酰转移酶抑制剂garcinol或LDH抑制剂galloflavin可减轻肝损伤并改善生存,提示PDHC和LDH是急性肝衰竭的治疗靶点。

要点

  • 小鼠急性肝衰竭时肝细胞核内PDHC和LDH水平及活性增加,伴核内乙酰辅酶A和乳酸浓度升高及组蛋白H3超乙酰化。
  • 组蛋白乙酰转移酶抑制剂garcinol减轻小鼠肝损伤并改善生存。
  • LDH抑制剂galloflavin(同时抑制PDHC)减轻小鼠肝坏死、凋亡和促炎因子表达,并呈剂量反应性改善生存。

核心结论

  • PDHC和LDH转位至细胞核导致核内乙酰辅酶A和乳酸浓度升高,引起组蛋白H3超乙酰化和损伤反应基因表达。
  • 抑制PDHC和LDH可减轻小鼠急性肝衰竭的肝损伤并改善生存,因此PDHC和LDH是急性肝衰竭的治疗靶点。

研究设计与样本

  • 研究评估了暴露于多种肝毒素(包括CD95抗体、α-鹅膏蕈碱和对乙酰氨基酚)的小鼠肝脏核组分中PDHC和LDH的水平及活性。
  • 对急性肝衰竭小鼠肝脏进行RNA-seq全基因组基因表达谱分析及基因本体富集分析。
  • 在敲低PDHA1或LDH-A的细胞系中以及CD95抗体处理后加入LDH抑制剂galloflavin的细胞中评估细胞活力。
  • 评估组蛋白乙酰转移酶抑制剂garcinol或galloflavin能否减轻急性肝衰竭小鼠的肝损伤。

主要发现

  • 急性肝衰竭小鼠肝脏核组分中PDHC和LDH水平及活性增加,且与核组分中乙酰辅酶A和乳酸浓度升高及组蛋白H3超乙酰化相关。
  • 急性肝衰竭小鼠肝脏基因表达提示组蛋白H3乙酰化增加诱导损伤反应相关基因表达。
  • garcinol降低组蛋白乙酰化,减轻急性肝衰竭小鼠肝损伤并改善生存。
  • 敲低PDHC或LDH提高暴露于促凋亡刺激的细胞活力。
  • galloflavin(同时抑制PDHC)减轻急性肝衰竭小鼠肝坏死、凋亡和促炎细胞因子表达,并呈剂量反应性改善生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute liver failure is a rapidly progressive deterioration of hepatic function resulting in high mortality and morbidity. Metabolic enzymes can translocate to the nucleus to regulate histone acetylation and gene expression. METHODS: Levels and activities of pyruvate dehydrogenase complex (PDHC) and lactate dehydrogenase (LDH) were evaluated in nuclear fractions of livers of mice exposed to various hepatotoxins including CD95-antibody, α-amanitin, and acetaminophen. Whole-genome gene expression profiling by RNA-seq was performed in livers of mice with acute liver failure and analyzed by gene ontology enrichment analysis. Cell viability was evaluated in cell lines knocked-down for PDHA1 or LDH-A and in cells incubated with the LDH inhibitor galloflavin after treatment with CD95-antibody. We evaluated whether the histone acetyltransferase inhibitor garcinol or galloflavin could reduce liver damage in mice with acute liver failure. RESULTS: Levels and activities of PDHC and LDH were increased in nuclear fractions of livers of mice with acute liver failure. The increase of nuclear PDHC and LDH was associated with increased concentrations of acetyl-CoA and lactate in nuclear fractions, and histone H3 hyper-acetylation. Gene expression in livers of mice with acute liver failure suggested that increased histone H3 acetylation induces the expression of genes related to damage response. Reduced histone acetylation by the histone acetyltransferase inhibitor garcinol decreased liver damage and improved survival in mice with acute liver failure. Knock-down of PDHC or LDH improved viability in cells exposed to a pro-apoptotic stimulus. Treatment with the LDH inhibitor galloflavin that was also found to inhibit PDHC, reduced hepatic necrosis, apoptosis, and expression of pro-inflammatory cytokines in mice with acute liver failure. Mice treated with galloflavin also showed a dose-response increase in survival. CONCLUSION: PDHC and LDH translocate to the nucleus, leading to increased nuclear concentrations of acetyl-CoA and lactate. This results in histone H3 hyper-acetylation and expression of damage response genes. Inhibition of PDHC and LDH reduces liver damage and improves survival in mice with acute liver failure. Thus, PDHC and LDH are targets for therapy of acute liver failure. LAY SUMMARY: Acute liver failure is a rapidly progressive deterioration of liver function resulting in high mortality. In experimental mouse models of acute liver failure, we found that two metabolic enzymes, namely pyruvate dehydrogenase complex and lactic dehydrogenase, translocate to the nucleus resulting in detrimental gene expression. Treatment with an inhibitor of these two enzymes was found to reduce liver damage and to improve survival.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ferriero R, Nusco E, De Cegli R, et al. Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure. J Hepatol. 2018. PMID: 29580866. doi:10.1016/j.jhep.2018.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。